210 related articles for article (PubMed ID: 23136004)
21. Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study.
Ikejiri K; Suzuki T; Muto S; Takama H; Yamawaki K; Miyazawa T; Urakawa I; Aoki Y; Otsuki A; Katsuoka F; Kinoshita K; Nangaku M; Akizawa T; Yamamoto M
Clin Exp Nephrol; 2024 Mar; 28(3):225-234. PubMed ID: 37962746
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats.
Giani JF; Burghi V; Veiras LC; Tomat A; Muñoz MC; Cao G; Turyn D; Toblli JE; Dominici FP
Am J Physiol Renal Physiol; 2012 Jun; 302(12):F1606-15. PubMed ID: 22492942
[TBL] [Abstract][Full Text] [Related]
23. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
Lambers Heerspink HJ; Chertow GM; Akizawa T; Audhya P; Bakris GL; Goldsberry A; Krauth M; Linde P; McMurray JJ; Meyer CJ; Parving HH; Remuzzi G; Christ-Schmidt H; Toto RD; Vaziri ND; Wanner C; Wittes J; Wrolstad D; de Zeeuw D
Nephrol Dial Transplant; 2013 Nov; 28(11):2841-50. PubMed ID: 24169612
[TBL] [Abstract][Full Text] [Related]
24. Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?
Rossing P
Nat Rev Nephrol; 2013 Mar; 9(3):128-30. PubMed ID: 23381371
[No Abstract] [Full Text] [Related]
25. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
[TBL] [Abstract][Full Text] [Related]
26. Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats.
Fredersdorf S; Weil J; Ulucan C; Birner C; Büttner R; Schubert T; Böger CA; Debl K; Muders F; Riegger GA; Luchner A
Naunyn Schmiedebergs Arch Pharmacol; 2007 Apr; 375(2):95-103. PubMed ID: 17333128
[TBL] [Abstract][Full Text] [Related]
27. Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes.
Zoja C; Cattaneo S; Fiordaliso F; Lionetti V; Zambelli V; Salio M; Corna D; Pagani C; Rottoli D; Bisighini C; Remuzzi G; Benigni A
Am J Physiol Renal Physiol; 2011 Nov; 301(5):F1114-23. PubMed ID: 21816757
[TBL] [Abstract][Full Text] [Related]
28. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Chin MP; Reisman SA; Bakris GL; O'Grady M; Linde PG; McCullough PA; Packham D; Vaziri ND; Ward KW; Warnock DG; Meyer CJ
Am J Nephrol; 2014; 39(6):499-508. PubMed ID: 24903467
[TBL] [Abstract][Full Text] [Related]
30. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney.
Reisman SA; Chertow GM; Hebbar S; Vaziri ND; Ward KW; Meyer CJ
J Am Soc Nephrol; 2012 Oct; 23(10):1663-73. PubMed ID: 22859857
[TBL] [Abstract][Full Text] [Related]
31. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
Ruggenenti P; Perna A; Gherardi G; Garini G; Zoccali C; Salvadori M; Scolari F; Schena FP; Remuzzi G
Lancet; 1999 Jul; 354(9176):359-64. PubMed ID: 10437863
[TBL] [Abstract][Full Text] [Related]
32. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
[TBL] [Abstract][Full Text] [Related]
33. Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
Ito M; Nangaku M
Kidney Int; 2019 Oct; 96(4):823-825. PubMed ID: 31543152
[TBL] [Abstract][Full Text] [Related]
34. Bardoxolone methyl and kidney function in CKD with type 2 diabetes.
Pergola PE; Raskin P; Toto RD; Meyer CJ; Huff JW; Grossman EB; Krauth M; Ruiz S; Audhya P; Christ-Schmidt H; Wittes J; Warnock DG;
N Engl J Med; 2011 Jul; 365(4):327-36. PubMed ID: 21699484
[TBL] [Abstract][Full Text] [Related]
35. The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling.
Bubb KJ; Kok C; Tang O; Rasko NB; Birgisdottir AB; Hansen T; Ritchie R; Bhindi R; Reisman SA; Meyer C; Ward K; Karimi Galougahi K; Figtree GA
Free Radic Biol Med; 2017 Jul; 108():585-594. PubMed ID: 28438659
[TBL] [Abstract][Full Text] [Related]
36. Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.
Mavrakanas TA; Cheva A; Kallaras K; Karkavelas G; Mironidou-Tzouveleki M
Pharmacology; 2010; 86(2):85-91. PubMed ID: 20689340
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Chin MP; Wrolstad D; Bakris GL; Chertow GM; de Zeeuw D; Goldsberry A; Linde PG; McCullough PA; McMurray JJ; Wittes J; Meyer CJ
J Card Fail; 2014 Dec; 20(12):953-8. PubMed ID: 25307295
[TBL] [Abstract][Full Text] [Related]
38. Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.
Yilmaz MI; Sonmez A; Saglam M; Kurt YG; Unal HU; Karaman M; Gok M; Cetinkaya H; Eyileten T; Oguz Y; Vural A; Mallamaci F; Zoccali C
Am J Nephrol; 2014; 40(3):208-14. PubMed ID: 25324042
[TBL] [Abstract][Full Text] [Related]
39. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
Chin MP; Bakris GL; Block GA; Chertow GM; Goldsberry A; Inker LA; Heerspink HJL; O'Grady M; Pergola PE; Wanner C; Warnock DG; Meyer CJ
Am J Nephrol; 2018; 47(1):40-47. PubMed ID: 29402767
[TBL] [Abstract][Full Text] [Related]
40. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.
Gilbert RE; Cox A; Wu LL; Allen TJ; Hulthen UL; Jerums G; Cooper ME
Diabetes; 1998 Mar; 47(3):414-22. PubMed ID: 9519748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
